secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001213900-24-064993
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA requires additional Phase 3 trial for Iomab-B; SIERRA alone not adequate for BLA filing
--------------------------------------------------------------------------------

- SIERRA met primary endpoint (dCR) with p<0.0001, but FDA now demands overall survival benefit in randomized head-to-head trial.
- New trial required: Iomab-B plus Flu/TBI vs cyclophosphamide plus Flu/TBI; no crossover allowed (vs 60% crossover in SIERRA).
- FDA suggests patient population could include all adult AML; specifics to be discussed in requested meeting.
- Actinium will seek a strategic partner for Iomab-B in U.S. after FDA interactions; focus shifts to Actimab-A, Iomab-ACT, preclinical.
- Management disappointed but will work with FDA; SIERRA supportive evidence for future BLA filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390024064993/0001213900-24-064993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390024064993/ea0210560-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-064993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer